Everything below concerns reverse-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-30. Numbers and descriptions here follow the published literature rather than marketing material.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
On the other hand, there will be no lasting muscle pain from lactate, and continuous aerobic activity is possible. Oxidation of odd-numbered saturated fatty acids may provide another mechanism, although very gradual, to up-regulate citric acid cycle during exercise. As the short-term regulation of ATP production becomes very weak after the exhaustion of glycogen, the medium-term regulation becomes enabled, but with a progressively weaker authority at higher purine nucleotide energy charge levels, which causes some differences in symptoms compared to McArdle's. In McArdle's, the highly active AMP deaminase, which additionally experiences amplification from the bloated AMP pool due to the lack of the moderating effect of myophosphorylase, is able to produce a readily observable "second wind" phenomenon almost exactly 7 minutes after a significant load increment. In AMPD deficiency, glycogen-less muscles will feel mostly the same by the time they become able to take another load increment. A load decrement may produce some sense of relief, though, if the pool of the citric acid cycle intermediates built up so far is sufficient to maintain full purine nucleotide energy charge at the lower load. It is unclear, what, if anything, does it take to unknowingly trigger rhabdomyolysis at this point, assuming the muscle cell is otherwise healthy.
=== Non-native introductions === Boletus edulis grows in some areas where it is not believed to be indigenous. It is often found underneath oak and silver birch in Hagley Park in central Christchurch, New Zealand, where it is likely to have been introduced, probably on the roots of container-grown beech, birch, and oak in the mid-19th century—around the time exotic trees began to be planted in the Christchurch area. Similarly, it has been collected in Adelaide Hills region of Australia in association with three species of introduced trees. It has been growing plentifully in association with pine forests in the southern KwaZulu-Natal Midlands in South Africa for more than 50 years and is believed to have been introduced with the import of pine trees. It also grows in pine plantations in neighboring Zimbabwe.
=== Selected articles === Adler, V., Yin, Z., Fuchs, S. Y., Benezra, M., Rosario, L., Tew, K. D., ... & Ronai, Z. E. (1999). Regulation of JNK signaling by GSTp. The EMBO journal, 18(5), 1321–1334. Townsend, D. M., Tew, K. D., & Tapiero, H. (2003). The importance of glutathione in human disease. Biomedicine & pharmacotherapy, 57(3-4), 145–155. Townsend, D. M., & Tew, K. D. (2003). The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene, 22(47), 7369–7375. Tapiero, H., & Tew, K. D. (2003). Trace elements in human physiology and pathology: zinc and metallothioneins. Biomedicine & Pharmacotherapy, 57(9), 399–411. Hayes, J. D., Dinkova-Kostova, A. T., & Tew, K. D. (2020). Oxidative stress in cancer. Cancer cell, 38(2), 167–197. Tew, K.D. Alkylating Agents. In: Principles & Practice of Oncology. Eds. DeVita, Hellman & Rosenberg. pp246–256, 2018. Tew, K.D. Protein S-Glutathionylation & Glutathione S-transferase P. In: Glutathione. Editor: Leopold Flohé. CRC Press. Chapter 12, 201–214, 2018.
=== Physical === Cardiovascular side effects can include hypertension or hypotension from a vasovagal response, Raynaud's phenomenon (reduced blood flow to the hands and feet), and tachycardia (increased heart rate). Sexual side effects in males may include erectile dysfunction, frequent erections, or prolonged erections. Gastrointestinal side effects may include abdominal pain, constipation, diarrhea, and nausea. Other potential physical side effects include appetite loss, blurred vision, dry mouth, excessive grinding of the teeth, nosebleed, profuse sweating, rhinitis medicamentosa (drug-induced nasal congestion), reduced seizure threshold, tics (a type of movement disorder), and weight loss. Dangerous physical side effects are rare at typical pharmaceutical doses. Amphetamine stimulates the medullary respiratory centers, producing faster and deeper breaths. In a normal person at therapeutic doses, this effect is usually not noticeable, but when respiration is already compromised, it may be evident. Amphetamine also induces contraction in the urinary bladder sphincter, the muscle which controls urination, which can result in difficulty urinating. This effect can be useful in treating bed wetting and loss of bladder control. The effects of amphetamine on the gastrointestinal tract are unpredictable. If intestinal activity is high, amphetamine may reduce gastrointestinal motility (the rate at which content moves through the digestive system); however, amphetamine may increase motility when the smooth muscle of the tract is relaxed.
=== Apodization in signal processing === The term apodization is used frequently in publications on Fourier-transform infrared (FTIR) signal processing. An example of apodization is the use of the Hann window in fast Fourier transform analyzers to smooth the discontinuities at the beginning and end of the sampled time record.
Sources: en.wikipedia.org
== Bibliography == Prentice, B. E., & Benell, D. (1992). "Determinants of empty returns by US refrigerated trucks: conjoint analysis approach". Canadian Journal of Agricultural Economics/Revue canadienne d'agroeconomie, 40(1), 109-127. doi:10.1111/j.1744-7976.1992.tb03680.x (abstract).
Muslims, India's largest religious minority, have contributed significantly to a synthetic Indo-Islamic religious culture. Sufism, the heterodox mystical movement in Islam found receptiveness among adherents of the medieval regional Shaivite and Vaishnavite traditions of Bhakti. Sikh gurdwaras and Sufi dargahs often attract both visitors and worshippers from other religions. India has monastic traditions such as that of Jain ascetics some of whom practice an extreme form of nonviolence (ahimsa) and Buddhist communities that have preserved ancient styles of meditations. This religious diversity coexists with religious endogamy—people rarely marry outside their faith. There is also religious segregation in housing—religious groups cluster by choice or necessity. Thus, India's religious picture has both rich intermixing and clear divisions.
=== Biology === The dragon's blood tree usually produces its flowers around March, though flowering does vary with location. The flowers tend to grow at the end of the branches. The plants have inflorescences and bear small clusters of fragrant, white, or green flowers. The fruits take five months to completely mature. The fruits are described as a fleshy berry, which changes from green to black as it gradually ripens. The fleshy berry fruit ends up being an orange-red color that contains one to three seeds. The berries are usually eaten and dispersed by birds and other animals. The tree's umbrella-shaped crown is adapted to arid conditions and is influenced by atmospheric moisture. Its leaves are scleromorphic, helping to prevent excessive water loss. The dragon's blood tree's distinctive umbrella shape is made possible by its unusual growth pattern. Unlike most monocots, Dracaena cinnabari undergoes secondary growth—a rare ability that allows its trunk to thicken over time. While its stem develops growth ring-like zones, these do not reliably indicate age since they form from irregular vascular bundle patterns rather than seasonal growth cycles. This growth mechanism differs significantly from dicot trees. Instead of forming continuous growth rings, D. cinnabari produces scattered vascular strands in its secondary tissue. This unique structure provides the necessary support for its broad crown while being efficient in its harsh, resource-limited environment.
== History == In 1999 it became a wholly owned subsidiary of the publicly held Cracker Barrel. On December 6, 2006, Logan's Roadhouse was sold to affiliates of Bruckmann, Rosser, Sherrill & Co., Canyon Capital Advisors LLC, and Black Canyon Capital LLC for $486 million. In 2010, private equity firm Kelso & Company acquired the company. On February 20, 2013, Mike Andres, a former McDonald's vice-president and former chief executive officer of Boston Market, replaced Tom Vogel as chief executive officer. On January 12, 2017, Hazem Ouf, former chief executive officer of American Blue Ribbon Holdings, was named president and chief executive officer. On August 8, 2016, Logan's Roadhouse filed for bankruptcy and announced plans to close eighteen of its 256 locations that are under-performing. The chain was reported to be struggling with heavy debt and falling sales. Locations closing in late September 2016, include, in Florida, two each in Kissimmee and Orlando, and one each in Mary Esther, Tampa, and Tallahassee; one in each of those cities: Macon, Georgia; Houston, Texas; Lafayette, Louisiana and Waynesboro, Virginia. On December 1, 2016, Logan's Roadhouse formally exited bankruptcy with a debt load reduced from about $400 million to $100 million. On November 1, 2018, Logan's Roadhouse announced that it was acquired by CraftWorks Restaurants & Breweries. On March 3, 2020, Craftworks filed for Chapter 11 Bankruptcy protection. On March 19, 2020, all open Logan's locations were temporarily closed amid the COVID-19 pandemic.
Researchers have developed a method to efficiently produce substantial quantities of heterologous viral glycoproteins within the allantoic cavity of embryonated chicken eggs. This technique utilizes a Sendai virus minigenome as a vector to express soluble variants of specific proteins, notably the human respiratory syncytial virus (HRSV) and human metapneumovirus (HMPV) fusion (F) proteins. These proteins are engineered without their transmembrane and cytoplasmic domains, facilitating their solubility. Overview of the methodology:
Sources: en.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.